BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38439023)

  • 1. Preimmunization with Listeria-vectored cervical cancer vaccine candidate strains can establish specific T-cell immune memory and prevent tumorigenesis.
    Zhang Y; Liu S; Chen M; Ou Q; Tian S; Tang J; He Z; Chen Z; Wang C
    BMC Cancer; 2024 Mar; 24(1):288. PubMed ID: 38439023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Listeria-vectored cervical cancer vaccine candidate strains reduce MDSCs via the JAK-STAT signaling pathway.
    Zhang Y; Lei Y; Ou Q; Chen M; Tian S; Tang J; Li R; Liang Q; Chen Z; Wang C
    BMC Biol; 2024 Apr; 22(1):88. PubMed ID: 38641823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced therapeutic efficacy of Listeria-based cancer vaccine with codon-optimized HPV16 E7.
    Duan F; Chen J; Yao H; Wang Y; Jia Y; Ling Z; Feng Y; Pan Z; Yin Y; Jiao X
    Hum Vaccin Immunother; 2021 Jun; 17(6):1568-1577. PubMed ID: 33449866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
    Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
    Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy with two attenuated Listeria strains carrying shuffled HPV-16 E6E7 protein causes tumor regression in a mouse tumor model.
    Su L; Zhang Y; Zhang X; Liu T; Liu S; Li Y; Jiang M; Tang T; Shen H; Wang C
    Sci Rep; 2021 Jun; 11(1):13404. PubMed ID: 34183739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Potential Herbal Adjuvant Combined With a Peptide-Based Vaccine Acts Against HPV-Related Tumors Through Enhancing Effector and Memory T-Cell Immune Responses.
    Song YC; Huang HC; Chang CY; Lee HJ; Liu CT; Lo HY; Ho TY; Lin WC; Yen HR
    Front Immunol; 2020; 11():62. PubMed ID: 32153559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic human papillomavirus vaccines: current clinical trials and future directions.
    Hung CF; Ma B; Monie A; Tsen SW; Wu TC
    Expert Opin Biol Ther; 2008 Apr; 8(4):421-39. PubMed ID: 18352847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
    Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
    J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 Cancers in Mice.
    Boilesen DR; Neckermann P; Willert T; Müller MD; Schrödel S; Pertl C; Thirion C; Asbach B; Wagner R; Holst PJ
    Cancer Immunol Res; 2023 Feb; 11(2):261-275. PubMed ID: 36534088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. THERAPEUTIC USE OF HUMAN PAPILLOMAVIRUS VACCINES IN CERVICAL LESIONS.
    Castro-Eguiluz D; Barquet-Muñoz SA; Arteaga-Gómez AC; Salcedo Hernández RA; Rodríguez-Trejo A; Gallardo-Rincón D; Serrano-Olvera JA; Aranda-Flores C
    Rev Invest Clin; 2020; 72(4):239-249. PubMed ID: 33064708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive vaccines for cervical cancer.
    Wheeler CM
    Salud Publica Mex; 1997; 39(4):283-7. PubMed ID: 9337561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
    Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
    Front Immunol; 2020; 11():927. PubMed ID: 32547541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.